A two-gene methylation signature for the diagnosis of bladder cancer in urine

Judith Bosschieter, Jakko A. Nieuwenhuijzen, Anouk Hentschel, Annina P. Van Splunter, Loes I. Segerink, André N. Vis, Saskia M. Wilting, Birgit I. Lissenberg-Witte, R. Jeroen A Van Moorselaar, Renske D.M. Steenbergen* (Corresponding Author)

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    1 Citation (Scopus)

    Abstract

    Aim: To analyze the potential of 14 cancer-associated genes, including six miRNAs, for bladder cancer (BC) diagnosis in urine. Patients & methods: DNA methylation levels of 14 genes were analyzed in urine of 72 BC patients and 75 healthy controls using quantitative methylation-specific PCR. Multivariate logistic regression analysis was used to determine an optimal marker panel. Results: Ten genes were significantly hypermethylated in BC patients. The GHSR/MAL combination showed the best diagnostic performance, reaching a sensitivity of 92% (95% CI: 86-99) and a specificity of 85% (95% CI: 76-94). Conclusion: We identified a novel two-gene panel with a high diagnostic accuracy for BC that can be applied in a noninvasive, urine-based test.

    Original languageEnglish
    Pages (from-to)337-347
    Number of pages11
    JournalEpigenomics
    Volume11
    Issue number3
    DOIs
    Publication statusPublished - 1 Feb 2019

      Fingerprint

    Keywords

    • biomarkers
    • methylation
    • molecular diagnostics
    • urinary bladder neoplasms
    • urine analysis

    Cite this

    Bosschieter, J., Nieuwenhuijzen, J. A., Hentschel, A., Van Splunter, A. P., Segerink, L. I., Vis, A. N., ... Steenbergen, R. D. M. (2019). A two-gene methylation signature for the diagnosis of bladder cancer in urine. Epigenomics, 11(3), 337-347. https://doi.org/10.2217/epi-2018-0094